» Articles » PMID: 15046534

Impact of ADHD and Its Treatment on Substance Abuse in Adults

Overview
Specialty Psychiatry
Date 2004 Mar 30
PMID 15046534
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a risk factor for substance abuse in adults. Additional psychiatric comorbidity increases this risk. ADHD is associated with different characteristics of substance abuse: substance abuse transitions more rapidly to dependence, and lasts longer in adults with ADHD than those without ADHD. Self-medication may be a factor in the high rate of substance abuse in adults with ADHD. While previous concerns arose whether stimulant therapy would increase the ultimate risk for substance abuse, recent studies have indicated that pharmacologic treatment appears to reduce the risk of substance abuse in individuals with ADHD. When treating adults with ADHD and substance abuse, clinicians should assess the relative severity of the substance abuse, the symptoms of ADHD, and any other comorbid disorders. Generally, stabilizing or addressing the substance abuse should be the first priority when treating an adult with substance abuse and ADHD. Treatment for adults with ADHD and substance abuse should include a combination of addiction treatment/psychotherapy and pharmacotherapy. The clinician should begin pharmacotherapy with medications that have little likelihood of diversion or low liability, such as bupropion and atomoxetine, and, if necessary, progress to the stimulants. Careful monitoring of patients during treatment is necessary to ensure compliance with the treatment plan.

Citing Articles

Validity of the Italian Version of DIVA-5: Semi-Structured Diagnostic Interview for Adult ADHD Based on the DSM-5 Criteria.

Di Lorenzo R, Latella E, Gualtieri F, Adriani A, Ferri P, Filippini T Healthcare (Basel). 2025; 13(3).

PMID: 39942433 PMC: 11816683. DOI: 10.3390/healthcare13030244.


Cannabis use and its association with psychopathological symptoms in a Swiss adult population: a cross-sectional analysis.

Mosandl C, Baltes-Fluckiger L, Kronschnabel J, Meyer M, Guessoum A, Herrmann O Front Public Health. 2024; 12:1356988.

PMID: 38841675 PMC: 11151851. DOI: 10.3389/fpubh.2024.1356988.


Screening for ADHD in Adult Patients With Epilepsy: Prevalence of Symptoms and Challenges to Diagnosis.

Nguyen T, Xiao E, Clark A, Shamim A, Maheshwari A J Atten Disord. 2023; 28(1):51-57.

PMID: 37694675 PMC: 10676030. DOI: 10.1177/10870547231197215.


The Use of Lisdexamfetamine to Treat ADHD in a Patient with Stimulant (Methamphetamine) Use Disorder.

Levine J, Swanson H Case Rep Psychiatry. 2023; 2023:5574677.

PMID: 37609571 PMC: 10442178. DOI: 10.1155/2023/5574677.


Attention-deficit/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: a Norwegian cohort study.

Vold J, Halmoy A, Chalabianloo F, Pierron M, Loberg E, Johansson K BMC Psychiatry. 2023; 23(1):479.

PMID: 37386438 PMC: 10308780. DOI: 10.1186/s12888-023-04980-w.